Industry Partner News: Santhera Launches U.S. Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy (DMD)


Santhera Pharmaceuticals announces the launch of a U.S. Expanded Access Program (EAP) referred to as BreatheDMD with idebenone for patients with DMD.

Through the BreatheDMD program, eligible patients in the U.S. with DMD who are 10 years and older and in respiratory function decline, can obtain access to investigational idebenone, at no cost, through a growing network of research centers across the U.S. 

“Several patient advocacy organizations in the U.S., including Parent Project Muscular Dystrophy (PPMD), Jett Foundation, CureDuchenne and the Muscular Dystrophy Association (MDA) have consistently mentioned that patients need access to additional treatment options, especially older patients in respiratory decline, and that these patients cannot afford to continue to wait. To help address this important unmet need, Santhera is proud to be launching this EAP, allowing eligible patients to obtain access to investigational idebenone,” said Thomas Meier, PhD, CEO of Santhera.

For Santhera's full announcement, please click here. For more about BreatheDMD, visit